Nanjing, China-based Triastek, a pharmaceutical company, has received FDA investigational new drug clearance to begin clinical studies on its 3D-printed medicine, T21, designed to treat ulcerative colitis.
3D-printed ulcerative colitis treatment receives FDA clearance to start clinical trials
